Investors & Media

Investors & Media

About Immatics

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. 

 

Stock Quote

Immatics N.V.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press & Media

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

read more

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME

read more

Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

read more